LeMaitre Vascular Inc (NASDAQ:LMAT) declared a quarterly dividend on Friday, February 23rd, Wall Street Journal reports. Investors of record on Thursday, March 22nd will be paid a dividend of 0.07 per share by the medical instruments supplier on Thursday, April 5th. This represents a $0.28 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Wednesday, March 21st. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.06.
LeMaitre Vascular (NASDAQ LMAT) opened at $36.16 on Friday. The stock has a market cap of $704.15, a P/E ratio of 42.54, a P/E/G ratio of 2.49 and a beta of 0.55. LeMaitre Vascular has a 1-year low of $22.95 and a 1-year high of $39.88.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $26.15 million for the quarter, compared to analyst estimates of $26.23 million. LeMaitre Vascular had a net margin of 17.03% and a return on equity of 16.93%. LeMaitre Vascular’s revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company posted $0.13 earnings per share. analysts anticipate that LeMaitre Vascular will post 0.98 EPS for the current fiscal year.
Several equities research analysts have weighed in on LMAT shares. BidaskClub downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Thursday, March 1st. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Canaccord Genuity restated a “hold” rating and issued a $33.00 target price on shares of LeMaitre Vascular in a research note on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $34.00.
In other news, CEO George W. Lemaitre sold 5,700 shares of LeMaitre Vascular stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $35.56, for a total transaction of $202,692.00. Following the completion of the sale, the chief executive officer now directly owns 3,259,263 shares in the company, valued at $115,899,392.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO George W. Lemaitre sold 42,036 shares of LeMaitre Vascular stock in a transaction on Monday, February 26th. The stock was sold at an average price of $35.68, for a total transaction of $1,499,844.48. Following the sale, the chief executive officer now owns 3,259,263 shares of the company’s stock, valued at $116,290,503.84. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 137,736 shares of company stock valued at $4,866,186. 23.70% of the stock is owned by insiders.
WARNING: This story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/03/23/lemaitre-vascular-inc-lmat-to-go-ex-dividend-on-march-21st.html.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.